The news: Wearable device maker Whoop raised $575 million in a new financing round that vaults it to a $10.1 billion valuation. The round was led by consumer health and tech investor Collaborative Fund, with participation from celebrity athletes LeBron James and Cristiano Ronaldo.

Why it matters: The funding supports Whoop’s push beyond fitness into more advanced health tracking, using AI and continuous monitoring to deliver personalized, proactive insights.

• Whoop plans to use much of the new funding for R&D to expand medical-grade capabilities, including glucose monitoring, according to a New York Times report.
• Whoop launched the Whoop MG (for medical grade) tracker last May, which includes blood pressure insights and an FDA-cleared electrocardiogram (ECG) sensor to monitor heart rhythms.
• In August, it launched Whoop Advanced Labs, which lets users purchase Quest lab tests through its app and combines clinician-reviewed results with device data for personalized health insights.

Whoop is also pushing into AI capabilities beyond health tracking:

• It adopted an AI-driven health operating system in October, promising proactive guidance that nudges users when it detects trends like rising stress or sleep issues.
• But competitors, including Oura Ring, Apple Watch, and Google’s Fitbit, are adding similar AI-driven health features.

Implications for health wearable and app companies: As wearable makers push beyond fitness tracking into more advanced health monitoring, consumer expectations are rising: 76% of US smartphone owners are interested in health apps that help them understand their health over time, according to an October Verily survey by The Harris Poll.

Companies will need to show real health value by translating features like heart monitoring or glucose insights into benefits consumers can easily understand. At the same time, the closer these tools move toward clinical territory, the greater the regulatory risk. Brands will need to clearly communicate what their products can and can’t do to avoid triggering FDA scrutiny. That will require marketing, product, and legal teams to align to balance credibility with compliance while making a clear case that these devices are trustworthy, valuable health tools.

This content is part of EMARKETER’s subscription Briefings, where we pair daily updates with data and analysis from forecasts and research reports. Our Briefings prepare you to start your day informed, to provide critical insights in an important meeting, and to understand the context of what’s happening in your industry. Not a subscriber? Click here to get a demo of our full platform and coverage.